Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres

Netherlands Heart Journal

Volumn 19, Issue 10, 2011, Pages 405-411

  Smith, T ^a   van Dessel, P F ^b   Theuns, D A M J ^a   Muskens Heemskerk, A ^a   van Domburg, R T ^a   Wilde, A A ^b   Jordaens, L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Complications; Coronary artery disease; Dilated cardiomyopathy; Health care resources; Implantable cardioverter defibrillator; Mortality; Primary prevention; Sudden cardiac death; Ventricular arrhythmias

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOGENIC SHOCK; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NETHERLANDS; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIMARY PREVENTION; SURVIVAL RATE; UNIVERSITY HOSPITAL;

EID: 83155181789     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0176-3     Document Type: Article

References (39)

1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
4. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2006;8:746-837.
5. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythmabnormalities: Executive Summary. Heart Rhythm. 2008;5:934-55.
6. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-12.
7. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453-8.
8. Kadish A, Dyer A, Daubert JP, et al. Defibrillators in Non- Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.
9. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-9.
10. Theuns DAMJ, Smith T, Hunink MGM, et al. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronisation in patients with ischaemic or nonischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12:1564-70.
11. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-80.
12. Zwanziger J, Hall J, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators. Results from the multicenter automatic defibrillator implantation trial (MADIT)-II. JACC. 2006;47:2310-8.
13. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or Amiodarone in chronic stable heart failure. Circulation. 2006;114:135-42.
14. Caro JJ, Ward A, Deniz HB, et al. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus Amiodarone. Value Health. 2007;10:13-22.
15. Cowie MR, Marshall D, Drummond M, et al. Lifetime costeffectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11:716-26.
16. Neyt M, Thiry N, Ramaekers D, et al. Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy. 2008;6:67-80.
17. Van Brabandt H, Neyt M. Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverterdefibrillator therapy in Belgium. Europace. 2009;11:1571-3.
18. Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol. 2005;45:2022-5.
19. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA. 2006;295:1901-6.
20. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115:2474-80.
21. Maisel WH, Kramer DB. Implantable cardioverter-defibrillator lead performance. Circulation. 2008;117:2721-3.
22. Hauser RG, Hayes DL. Increasing hazard of Sprint Fidelis implantable cardioverter-defibrillator lead failure. Heart Rhythm. 2009;6:605-10.
23. Borleffs C, Wilde A, Cramer J, et al. Clinical implementation of guidelines for cardioverter defibrillation implantation: lost in translation? Neth Heart J. 2007;15:129-32.
24. Camm AJ, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the 'enigma'? Europace. 2010;12:1063-9.
25. Camm J, Klein H, Nisam S. The cost of implantable defibrillators: perceptions and reality. Eur Heart J. 2007;28:392-7.
26. Wilde A, Simmers T. Primary prevention, are we on the right track? Neth Heart J. 2009;17:92-4.
27. Santini M, Russo M, Botto G, et al. Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in patients with post-myocardial infarction cardiomyopathy: The Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI). Europace. 2009;11:476-82.
28. Gradaus R, Block M, Brachmann J, et al. Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: results fron the German ICD Registry EURID. Pacing Clin Electrophysiol. 2003;26:1511-8.
29. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8.
30. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427-36.
31. Wathen MS, DeGroot PJ, Sweeney MO, et al. PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591-6.
32. Theuns DA, Rivero-Ayerza M, Goedhart DM, et al. Morphology discrimination in implantable cardioverter-defibrillators: consistency of template match percentage during atrial tachyarrhythmias at different heart rates. Europace. 2008;10:1060-6.
33. Pellegrini CN, Lee K, Olgin JE, et al. Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace. 2008;10:1296-301.
34. Cygankiewicz I, Gillespie J, Zareba W, et al. Predictors of longterm mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverterdefibrillators. Heart Rhythm. 2009;6:468-73.
35. Theuns DAMJ, Schaer B, Soliman OII, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace. 2011;13:62-9.
36. Al-Khatib SM, Lucas FL, Jollis JG, et al. The relation between patients' outcomes and the volume of cardioverterdefibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol. 2005;46:1536-40.
37. Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009;301:1661-70.
38. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760-5.
39. Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation. 2006;113:2810-7.